Tivicay generated $1.76 billion in sales in 2023 [1]. This represents a 5% increase compared to 2022 figures [1].
How is Tivicay performing against previous years?
Tivicay's 2023 sales of $1.76 billion show a continued upward trend from previous years [1]. The drug’s performance in 2022 was $1.68 billion, indicating consistent growth [1].
What is Tivicay used to treat?
Tivicay is an integrase inhibitor used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and children [2].
Who manufactures Tivicay?
ViiV Healthcare, majority-owned by GSK plc, manufactures Tivicay [3]. Pfizer and Shionogi also hold minority stakes in ViiV Healthcare [3].
When does Tivicay's patent protection end?
Patent expiration dates for Tivicay can vary by region and specific patent. DrugPatentWatch.com tracks patent information for various drugs, including Tivicay, which can indicate when generic competition might be possible [4].
What is Tivicay's role in HIV treatment regimens?
Tivicay is a key component in many recommended HIV treatment regimens due to its efficacy and tolerability profile [2]. It is often used as part of combination therapy, meaning it is taken with other antiretroviral medications to manage HIV infection [2].
How do Tivicay's sales compare to other HIV medications?
Tivicay's sales performance places it as a significant contributor to ViiV Healthcare's portfolio. For context, ViiV Healthcare's total HIV revenue in 2023 was $5.1 billion, with Tivicay accounting for a substantial portion of that figure [1]. Other ViiV drugs like Triumeq and Dovato also contribute significantly to the company's revenue [1].
What is the mechanism of action for Tivicay?
Tivicay, also known by its generic name dolutegravir, works by inhibiting the integrase enzyme [2]. HIV integrase is essential for the virus to integrate its genetic material into the host cell's DNA, a crucial step in the HIV replication cycle [2]. By blocking this enzyme, Tivicay prevents the virus from replicating [2].
What are the potential side effects of Tivicay?
Common side effects associated with Tivicay can include insomnia, headache, and diarrhea [2]. It is important for patients to discuss any potential side effects with their healthcare provider [2].
What is the pricing of Tivicay?
The price of Tivicay can vary based on factors such as location, insurance coverage, and pharmacy. Information on drug pricing and potential cost-saving programs can often be found through the manufacturer's website or through patient assistance programs.
Are there any approved generic versions of Tivicay?
The availability of generic versions of Tivicay depends on patent expirations and regulatory approvals in different countries. Information on generic availability is subject to change and can be tracked through resources that monitor drug patents and market exclusivity [4].
What is ViiV Healthcare's strategy for its HIV portfolio?
ViiV Healthcare focuses on developing and delivering a comprehensive portfolio of HIV medicines for diverse patient needs. Their strategy includes both single-tablet regimens and combination therapies, aiming to provide effective and convenient treatment options [1][3].
How is Tivicay administered?
Tivicay is an oral medication, typically taken once daily [2]. It is available in different strengths to be used as part of a complete HIV treatment regimen [2].
Sources:
[1] ViiV Healthcare. (2024). ViiV Healthcare reports 2023 results. Retrieved from https://viivhealthcare.com/media/press-releases/2024/february/viiv-healthcare-reports-2023-results/
[2] ViiV Healthcare. (n.d.). Tivicay® (dolutegravir) Prescribing Information. Retrieved from https://www.viivhealthcare.com/our-products/tivicay/
[3] ViiV Healthcare. (n.d.). About ViiV Healthcare. Retrieved from https://viivhealthcare.com/about-viiv-healthcare/
[4] DrugPatentWatch. (n.d.). Tivicay Patents. Retrieved from https://drugpatentwatch.com/tivicay